• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Trying the Long Side of Vertex's Stock Again

After pharmaceutical company breaks out, charts suggest now is the time to go back in.
By BRUCE KAMICH
Mar 16, 2018 Updated Mar 16, 2018 | 01:38 PM EDT
Stocks quotes in this article: VRTX

Vertex Pharmaceuticals (VRTX) broke out to new highs this month, breaking the highs of July and late January. Can the rally continue and what price targets might the charts reveal? We last checked the indicators back in early September, and said, "The bull market in shares of VRTX does not want to stop. Trade from the long side, but have a sell stop below $149 in case of a reversal. On the upside $195 and $200 are our next potential price targets." Let's check how the charts look now.

In this daily bar chart of VRTX, below, we can see that longs would have exited in late October as prices broke to the downside. A new uptrend did not get underway until late December and a pullback February may have shaken out short-term traders again. This month VRTX finally broke over its July and January highs. Currently VRTX is above the rising 50-day moving average line and the rising 200-day line. VRTX dipped towards the 200-day line in early December and again in February. The On-Balance-Volume (OBV) line has been in a new rising trend since early December and the Moving Average Convergence Divergence (MACD) oscillator is above the zero line but poised for a possible crossover and take profits sell signal.

In this weekly bar chart of VRTX, below, we can see a base in 2016 and a strong rally beginning in March of 2017. The rising 40-week moving average line was successfully tested twice.The weekly OBV line has been positive since late 2016. The weekly MACD oscillator has recently turned up to a fresh outright go long signal from above the zero line.

In this Point and Figure chart of VRTX, below, we can see a large accumulation pattern and a triple top breakout. A $197.78 price target is shown.

Bottom line -- our previous trade suggestion on VRTX was stopped out but that does not mean we don't get back on the horse. Traders could approach VRTX from the long side again looking for gains to the round number of $200 risking below $155 now.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual equities.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login